{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-115933","form_type":"8-K","ticker":"PTGX","cik":"0001377121","company_name":"Protagonist Therapeutics, Inc","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.370462+00:00","generated_at":"2026-06-22T03:12:20.977749+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Protagonist Q3 net loss $31.2M, cash $267.4M; rusfertide Phase 3 enrollment delayed to H2 2023","bullets":["Net loss $31.2M ($0.64 per share) vs $33.8M ($0.70) in Q3 2021; no license revenue vs $10.3M.","Cash and securities $267.4M as of Sep 30; expected to fund operations through end of 2024.","Phase 3 VERIFY enrollment completion expected H2 2023 due to site staff shortages.","Appointed Arturo Molina, M.D., M.S. as CMO, prioritizing rusfertide program.","De-prioritized PN-943; no further internal resources; seeking out-licensing."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-115933","json":"https://secwatch.observer/filing/0001104659-22-115933.json","markdown":"https://secwatch.observer/filing/0001104659-22-115933.md","text":"https://secwatch.observer/filing/0001104659-22-115933.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1377121/000110465922115933/0001104659-22-115933-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1377121/000110465922115933/tm2229956d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T03:12:20.977749+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"89b0736ad0419041057e6821040f8a8802dff93e","claim":"Protagonist Therapeutics, Inc reported financial results for the third quarter ended September 30, 2022.","evidence_excerpt":"Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist” or “the Company”) today reported financial results for the third quarter ended September 30, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465922115933/0001104659-22-115933-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}